PubMed Health⌕ Search

Biomedical subjects

S G Wyld

Publications and source records attributed to S G Wyld.

24 records · Page 2Linked to original sources
PubMed1975

Characterization of Mycoplasmatales virus-laidlawii 3.

Purified preparations of Mycoplasmatales virus-laidlawii 3 were negatively stained and studied by electron microscopy. They were seen to consist of uniform sized particles having a polyhedral head, 57 nm by 61 nm, and a short tail, 25 nm long, joined to the head at one vertex by a collar. The particles were shown to have buoyant densities of 1-477 g/ml in CsC1, 1-32 g/ml and 1-26 g/ml in potassium tartrate and a sedimentation coefficient, S20,W, OF 290 +/- 13. They are composed of 35-2% double-stranded DNA and five structural polypeptides with approximate mol. wt. of 172000, 81000 73000, 68000 and 43000. The classification of the virus from its morphology and chemical properties is discussed.

Acholeplasma laidlawii↗
PubMedDate not supplied

Immunization with a peptide derived from the G glycoprotein of bovine respiratory syncytial virus (BRSV) reduces the incidence of BRSV-associated pneumonia in the natural host.

Previous reports demonstrate that synthetic peptides corresponding to the amino acid region 174-187 of G glycoprotein from subgroups A and B human respiratory syncytial virus (HRSV), containing a Cys-->Ser substitution at position 186, confer complete resistance to immunized BALB/c mice against infection with the respective virus. In this report, we show that a Cys186-->Ser substituted peptide (BG/174-187) representing the corresponding region of the bovine (B) RSV G glycoprotein conferred complete protection of mice against BRSV challenge, suggesting that the 174-187 region of RSV G glycoproteins constitutes a dominant protective epitope which has been maintained throughout evolution. Furthermore, immunization of calves with peptide BG/174-187 efficiently induced the production of antibodies capable of recognizing both the parental G glycoprotein and peptide BG/174-187. Following challenge with live BRSV, although none of the animals were protected from upper respiratory tract disease, there were little or no gross pneumonic lesions in the four peptide-immunized calves. In contrast, moderate to extensive pneumonic lesions were observed in 2 out of 3 calves in the control group. Our results thus suggest that peptide BG/174-187 efficiently prevented BRSV-associated pneumonia in the natural host. The use of this system as a model is quite promising with regard to the development of a human synthetic vaccine.

Animals↗